Search Results for "Astrazeneca Tremelimumab Asco 2012"
Original Source: Cytotoxic lymphocyte associated molecule 4 CTLA 4 CD152
Cytotoxic lymphocyte-associated molecule-4 (CTLA-4, CD152) is a member of the CD28 receptor family which is expressed on the surface of Helper T cells. CTLA-4 is similar to the T-cell costimulatory protein CD28, and both molecules bind to their ligands of...
Matching Channels
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009. it is a global company, working in more than 100 countries, and em...
Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...
Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug
Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...
Seroquel, an atypical antipsychotic medication has annual sales of $3.1m (in 2009), and based on annual sales, ranks 5th in the world. It is produced by AstraZeneca Pharmaceuticals as a quetiapine f...
Nexium is the 2nd most profitable drug in 2009, according to 2009 annual sales figures, where it generated just over $5m in sales for its company, AstraZeneca Pharmaceuticals. Nexium is a pr...
Matching News
Tremelimumab does not improve survival in advanced melanoma
NEW YORK (Reuters Health) - Patients with advanced melanoma who received tremelimumab in a phase III trial had longer-lasting responses compared to patients who got standard chemotherapy, but no b...
ASCO: Empty-handed AZ seeks attention for pipeline amid oncology frenzy
AstraZeneca is distracting attention from its lack of Phase III fireworks at this year's ASCO meeting by trumpeting the progression of three of its cancer products into late-stage trials. But its exc...
In her third and final report from this year’s ASCO conference, Nell Barrie reflects on her personal highlights of the meeting. Even though ASCO is one of the world’s biggest cancer treatment conf...
Judgment in Case C-457/10 P AstraZeneca v Commission
Luxembourg, 6 December 2012--The Court dismisses the appeal of the AstraZeneca group, which abused its dominant position by preventing the marketing of generic products replicating Losec AstraZeneca A...
The 2012 New York ASCO Checklist
On June 1, cancer scientists and drugmakers will flock to Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO). The gathering is so prominent that many pharmaceutical com...
AstraZeneca issues update on accelerated oncology pipeline in advance of 2013 ASCO Annual Meeting
First patient enrolled in Phase III clinical trial...
Merck, AstraZeneca amend long-standing partnership
Drugmakers Merck & Co. and AstraZeneca PLC have amended their U.S. partnership to give AstraZeneca a 2014 buyout option that could cost more than $400 million.The companies said Wednesday that London-...
Proffice and AstraZeneca Plan to Extend Their Relationship
Proffice has been appointed by AstraZeneca as its Managed Service Provider for all staffing services for AstraZeneca's operations in Sweden. Based on this, AstraZeneca and Proffice have agreed to ...
Matching PubMed Articles
PURPOSE: Safety and efficacy of tremelimumab (CP-675,206), a fully human anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) monoclonal antibody, were assessed in patients with treatment-refracto...
Anti-CTLA-4 monoclonal antibodies (mAb) that block the interaction of CTLA-4 with CD80 and CD86 such as tremelimumab and ipilimumab are currently being tested in the clinic for cancer treatment exploi...
Literature Review January-March 2011.
The Discovery of MMP7 Inhibitors Exploiting a Novel Selectivity Trigger.
